Targeting of FAP with a humanized antibody, sibrotuzumab, in patients with metastatic CRC also demonstrated good tolerability but did not result in tumor control, indicating the presence of dominant alternative mechanisms that hamper an effective anti-tumor response, once again stressing the need for a combinatorial approach to obtain an effective cancer treatment [107]. This evidence concerns the gene FAP and neoplasm.